TCONUnknownMicro-Cap
Tracon Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Tracon Pharmaceuticals, Inc. (TCON), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are TCON insiders buying or selling?
Tracon Pharmaceuticals, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since March 2018, Trabud has recorded 101 Form 4 filings for TCON: 97 buys ($32.5M) and 4 sells ($2.5M).
Source: SEC EDGAR Form 4
Key Statistics (March 2018 – Nov 14, 2023)
Total Form 4 filings
101
SEC EDGAR
Insider filers
18
Insider buys (97)
$32.5M
Insider sells (4)
$2.5M
Insider sentiment
Net buyingNet insider flow of $29.9M in net buying since March 2018.
Recent TCON insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 14, 2023 | Opaleye Management Inc. | 10% Owner | Sale | 4.8M | $0.29 | $1.4M | SEC ↗ |
| Apr 28, 2023 | Charles Theuer | President and CEO | Purchase | 51.0K | $0.74 | $37.9K | SEC ↗ |
| Mar 13, 2023 | Opaleye Management Inc. | 10% Owner | Purchase | 174.5K | $1.38 | $240.8K | SEC ↗ |
| Mar 2, 2023 | Charles Theuer | President and CEO | Purchase | 5.0K | $1.52 | $7.6K | SEC ↗ |
| Jan 19, 2023 | Charles Theuer | President and CEO | Purchase | 6.8K | $1.62 | $11.0K | SEC ↗ |
| Jan 19, 2023 | William R Larue | Director | Sale | 120 | $1.26 | $150.64 | SEC ↗ |
| Jan 3, 2023 | Scott B. Brown | Chief Financial Officer | Purchase | 3.5K | $1.49 | $5.2K | SEC ↗ |
| Dec 16, 2022 | Opaleye Management Inc. | 10% Owner | Purchase | 167.5K | $1.25 | $209.9K | SEC ↗ |
| Dec 15, 2022 | Charles Theuer | President and CEO | Purchase | 23.0K | $1.29 | $29.8K | SEC ↗ |
| Dec 8, 2022 | Opaleye Management Inc. | 10% Owner | Sale | 1.5K | $1.44 | $2.2K | SEC ↗ |
| Nov 22, 2022 | Charles Theuer | President and CEO | Purchase | 13.9K | $1.41 | $19.6K | SEC ↗ |
| Nov 4, 2022 | Charles Theuer | President and CEO | Purchase | 9.2K | $1.52 | $14.0K | SEC ↗ |
| Nov 3, 2022 | Charles Theuer | President and CEO | Purchase | 6.0K | $1.59 | $9.5K | SEC ↗ |
| Oct 19, 2022 | Opaleye Management Inc. | 10% Owner | Purchase | 12.5K | $1.65 | $20.6K | SEC ↗ |
| Oct 11, 2022 | Charles Theuer | President and CEO | Purchase | 5.0K | $1.77 | $8.8K | SEC ↗ |
| Oct 5, 2022 | Charles Theuer | President and CEO | Purchase | 5.0K | $1.67 | $8.3K | SEC ↗ |
| Oct 3, 2022 | Opaleye Management Inc. | 10% Owner | Purchase | 9.4K | $1.74 | $16.4K | SEC ↗ |
| Sep 28, 2022 | Opaleye Management Inc. | 10% Owner | Purchase | 1.7K | $1.69 | $2.9K | SEC ↗ |
| Sep 26, 2022 | Charles Theuer | President and CEO | Purchase | 5.0K | $1.76 | $8.8K | SEC ↗ |
| Sep 22, 2022 | Opaleye Management Inc. | 10% Owner | Purchase | 17.3K | $1.73 | $29.9K | SEC ↗ |
| Sep 20, 2022 | Opaleye Management Inc. | 10% Owner | Purchase | 10.0K | $1.85 | $18.5K | SEC ↗ |
| Sep 19, 2022 | Opaleye Management Inc. | 10% Owner | Purchase | 5.0K | $1.87 | $9.4K | SEC ↗ |
| Sep 14, 2022 | Scott B. Brown | Chief Financial Officer | Purchase | 2.5K | $2.02 | $5.0K | SEC ↗ |
| Jul 26, 2022 | Opaleye Management Inc. | 10% Owner | Purchase | 2.3K | $1.72 | $3.9K | SEC ↗ |
| Jul 25, 2022 | Charles Theuer | President and CEO | Purchase | 4.5K | $1.85 | $8.3K | SEC ↗ |
Showing the 25 most recent of 101 Form 4 filings for Tracon Pharmaceuticals, Inc..
Most active TCON insiders
- Charles Theuer38 filings
- Opaleye Management Inc.35 filings
- Scott B. Brown5 filings
- Ikarian Capital, LLC4 filings
- Mark C Wiggins3 filings
Ask anything about TCON insider activity
Use Trabud's AI agent to query Tracon Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me TCON CEO purchases this year" or compare it against any other ticker.
Open the AI agentTCON insider trading FAQ
Are Tracon Pharmaceuticals, Inc. insiders buying or selling?
Tracon Pharmaceuticals, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since March 2018, Trabud has recorded 101 Form 4 filings for TCON: 97 buys ($32.5M) and 4 sells ($2.5M). Over the full record that is net buying of $29.9M.
How many insiders trade TCON stock?
18 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Tracon Pharmaceuticals, Inc.. The most recent filing was accepted on Nov 14, 2023.
Where does Trabud get TCON insider trading data?
All TCON insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.